1. Scrip
  2. >>Therapy Areas

Shire's Vyvanse wins 1st 'binge-eating' indication

 
• By Donna Young

Shire picked up another indication for Vyvanse (lisdexamfetamine dimesylate) – winning the first approval in the US for a drug to help curb episodes of binge-eating in adults with the disorder.

Shire picked up another indication for Vyvanse (lisdexamfetamine dimesylate) – winning the first approval in the US for a drug to help curb episodes of binge-eating in adults with the disorder.

Binge-eating disorder may lead to weight gain and to health problems related to obesity, the FDA noted.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.